Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma | Zendy

Jessica Ley | Zendy; Paul Mehan | Zendy; Tanya M. Wildes | Zendy; Wade L. Thorstad | Zendy; Hiram A. Gay | Zendy; Loren S. Michel | Zendy; Brian Nussenbaum | Zendy; Kathryn Trinkaus | Zendy; Douglas R. Adkins | Zendy

Open Access

Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Author(s) -

Jessica Ley,

Paul Mehan,

Tanya M. Wildes,

Wade L. Thorstad,

Hiram A. Gay,

Loren S. Michel,

Brian Nussenbaum,

Kathryn Trinkaus,

Douglas R. Adkins

Publication year - 2013

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000355194

Subject(s) - cetuximab , cisplatin , medicine , head and neck squamous cell carcinoma , head and neck cancer , oncology , hazard ratio , radiation therapy , group b , chemotherapy , confidence interval , cancer , colorectal cancer

Whether or not cisplatin and cetuximab are similarly effective in improving outcomes when added to radiation therapy (RT) in squamous cell carcinoma of the head and neck is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research